Management of Gouty Arthritis

Acute Gout Attack Management

• The primary objective of acute gout attack management is rapid control of inflammation and pain, not correction of hyperuricemia during the acute attack, according to the American College of Rheumatology 1, 2
• NSAIDs are an appropriate first-line choice for most patients without contraindications, with COX-2 inhibitors causing fewer total adverse events and fewer withdrawals compared to traditional NSAIDs 1, 2
• Low-dose colchicine is equally effective as high-dose colchicine but with significantly fewer gastrointestinal adverse events, and is the preferred dosing strategy when colchicine is selected 1, 2
• Corticosteroids are particularly valuable in patients with contraindications to NSAIDs or colchicine, and can be administered orally, intravenously, or intra-articularly 1, 2
• Initiate treatment within 24 hours of symptom onset for optimal outcomes, and never discontinue established urate-lowering therapy during an acute attack 1, 2

Chronic Gout Management

• Absolute indications for starting urate-lowering therapy (ULT) include any tophus or tophi on clinical exam or imaging, frequent attacks (≥2 per year), and history of urolithiasis, according to the American College of Rheumatology 3, 1, 2
• The minimum target serum uric acid level is <6 mg/dL for all patients, with some patients requiring <5 mg/dL to improve signs and symptoms, particularly with tophi 3, 1, 2
• Allopurinol is the first-line urate-lowering agent, with a starting dose of 100 mg/day for most patients and 50 mg/day in chronic kidney disease stage 4 or worse 1, 2
• Titrate allopurinol every 2-5 weeks by 100 mg increments until serum uric acid <6 mg/dL, with a maximum dose of 800 mg/day 1, 2
• Prophylactic anti-inflammatory medication, such as low-dose colchicine or NSAIDs, is essential when starting ULT to prevent acute gout attacks, and should be continued for a minimum of 8 weeks 1, 2

Key Algorithmic Approach

• For acute attack, start anti-inflammatory therapy within 24 hours, continue any established urate-lowering therapy without interruption, and add topical ice and joint rest 1, 2
• For chronic management, determine if ULT is indicated, start allopurinol 100 mg/day (50 mg if CKD stage 4+), and simultaneously start prophylaxis with low-dose colchicine or NSAID 1, 2, 3
• Titrate allopurinol every 2-5 weeks by 100 mg increments until serum uric acid <6 mg/dL, and continue prophylaxis for minimum 8 weeks and until attack-free with target achieved 1, 2

Common Pitfalls to Avoid

• Stopping urate-lowering therapy during acute attacks undermines long-term control, and starting ULT without prophylaxis virtually guarantees flares and treatment abandonment 1, 2
• Inadequate allopurinol dose titration and discontinuing ULT after symptoms resolve can also lead to poor outcomes, according to the American College of Rheumatology 2, 3
• Using high-dose colchicine for acute attacks is not recommended, as low-dose is equally effective with fewer adverse events 1, 2

Acute Gout Management in Patients with Hepatic Impairment

First‑Line Anti‑Inflammatory Therapy

Therapies to Avoid in Hepatic Impairment

NSAIDs

Colchicine

Adjunctive Measures

Prophylaxis When Initiating Urate‑Lowering Therapy

Acute Gout Flare Management

First‑Line Anti‑Inflammatory Therapy

• Corticosteroids, NSAIDs, and low‑dose colchicine are equally appropriate first‑line options for an acute gout flare, with strong evidence supporting their use. 7
• The choice among these agents should be based on individual contraindications and comorbidities rather than on superiority of any class. 7, 8

Timing of Treatment Initiation

• Anti‑inflammatory therapy should be started within 24 hours of symptom onset to achieve optimal pain relief and faster resolution of the attack. 9, 8
• Initiating low‑dose colchicine later than 36 hours after symptom onset reduces its efficacy. 9
• Delaying treatment beyond 24 hours diminishes effectiveness regardless of the selected agent. 9, 8

NSAID Recommendations

• Use FDA‑approved NSAIDs (e.g., naproxen, indomethacin, sulindac) or any NSAID at full anti‑inflammatory dosing; continue at this dose until the attack is completely resolved. 9, 8

Low‑Dose Colchicine Regimen

• Administer 1.2 mg orally immediately, followed by 0.6 mg one hour later (total 1.8 mg). This low‑dose schedule is as effective as high‑dose regimens but causes significantly fewer gastrointestinal adverse events. 7, 9

Corticosteroid Options

• Oral prednisone 0.5 mg/kg per day (typically 30–40 mg) for 5–10 days, or 2–5 days followed by a 7–10‑day taper.
• Intramuscular triamcinolone acetonide 60 mg (optional oral taper).
• Intra‑articular corticosteroid dosing varies by joint size and is especially useful for mono‑articular attacks. All corticosteroid regimens are supported by clinical evidence. 9, 8

Duration of Anti‑Inflammatory Therapy

• Maintain the chosen anti‑inflammatory agent at full therapeutic dose until the acute attack is fully resolved, typically 5–14 days depending on severity. 9, 8

Management of Urate‑Lowering Therapy (ULT)

• Do not discontinue ongoing ULT (e.g., allopurinol, febuxostat) during an acute flare; continuation prevents prolongation of symptoms and preserves long‑term urate control. 7, 9, 8
• Do not initiate ULT during a first gout attack or any acute flare in most patients; initiation should be deferred until after the attack has fully resolved. 7

Combination Therapy for Severe Polyarticular Attacks

• For severe pain (>6/10) involving multiple large joints or a polyarticular distribution, combine two anti‑inflammatory agents from different classes (e.g., corticosteroid + colchicine or corticosteroid + NSAID). This approach is evidence‑based for improved symptom control. 9, 8

Common Pitfalls to Avoid

• High‑dose colchicine (1.2 mg followed by 0.6 mg hourly) yields no additional efficacy but markedly increases gastrointestinal toxicity compared with the low‑dose regimen. 7, 9
• Stopping anti‑inflammatory therapy before complete symptom resolution leads to rebound flares. 9, 8
• Discontinuing established ULT during an acute flare prolongs the attack and destabilizes urate control. 7, 9
• Initiating ULT (allopurinol or febuxostat) during an acute attack can paradoxically worsen or extend symptoms; therapy should begin only after the flare has resolved. 7

Alternative Biologic Therapy for Refractory Cases

• Canakinumab (150 mg subcutaneously, single dose) is FDA‑approved for symptomatic treatment of gout flares when NSAIDs, colchicine, and corticosteroids are contraindicated, not tolerated, or ineffective, and repeated corticosteroid courses are unsuitable. It is reserved for patients who have failed or cannot use all three conventional first‑line therapies. 9